EGFR and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), activating mutations in the epidermal growth factor receptor (EGFR) gene have been effectively targeted by tyrosine kinase inhibitors (TKIs) such as erlotinib, resulting in improved progression-free survival.